1. Home
  2. TPVG vs TNXP Comparison

TPVG vs TNXP Comparison

Compare TPVG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriplePoint Venture Growth BDC Corp.

TPVG

TriplePoint Venture Growth BDC Corp.

HOLD

Current Price

$4.48

Market Cap

224.9M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$9.92

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPVG
TNXP
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.9M
199.7M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
TPVG
TNXP
Price
$4.48
$9.92
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$5.90
N/A
AVG Volume (30 Days)
257.3K
544.8K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
17.66%
N/A
EPS Growth
N/A
91.75
EPS
0.23
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
$7.67
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
29.85
52 Week Low
$4.41
$10.03
52 Week High
$7.24
$69.65

Technical Indicators

Market Signals
Indicator
TPVG
TNXP
Relative Strength Index (RSI) 37.96 35.99
Support Level N/A N/A
Resistance Level $5.70 $13.18
Average True Range (ATR) 0.16 0.93
MACD -0.00 -0.22
Stochastic Oscillator 15.32 1.20

Price Performance

Historical Comparison
TPVG
TNXP

About TPVG TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: